Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Mariella D'Adda, Valeria Cancelli, Sofia Terlizzi, Annamaria Pelizzari, Samantha Ferrari, Diego Bertoli, Chiara Bottelli, Nicola Bianchetti, Annalisa Peli, Ilaria Accarino, Carlotta Giupponi, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 6612.

https://doi.org/10.1182/blood-2024-210714

Published: 2024

Journal Articles

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Angelo Belotti, Rossella Ribolla, Claudia Crippa, Marco Chiarini, Viviana Giustini, Samantha Ferrari, Annalisa Peli, Chiara Cattaneo, Aldo Roccaro, Barbara Frittoli, Marta Salis, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2022) 140 (Supplement 1): 1140–1141.

https://doi.org/10.1182/blood-2022-157520

Published: 2022

Journal Articles

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Angelo Belotti, Rossella Ribolla, Alberta Villanacci, Marco Chiarini, Viviana Giustini, Giulia Vittoria Facchetti, Claudia Crippa, Valeria Cancelli, Samantha Ferrari, Annalisa Peli, Chiara Bottelli, Chiara Cattaneo, Chiara Saeli, Aldo M. Roccaro, Luigi Grazioli, Giuseppe Rossi, Alessandra Tucci

Blood (2021) 138 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2021-147694

Published: 2021

Journal Articles

External Validation of Diffusion Weighted Whole Body MRI (DW-MRI) Response Assessment Category (RAC) Criteria Proposed By the Myeloma Response Assessment and Diagnosis System (MY-RADS) Imaging Recommendations: Prognostic Role of Imaging Response after Transplant in Multiple Myeloma and Comparison with MRD Evaluation By Flow Cytometry

Angelo Belotti, Rossella Ribolla, MD, Valeria Cancelli, MD, Alberta Villanacci, Valentina Angelini, Samantha Ferrari, Annalisa Peli, MD, Chiara Cattaneo, MD, Marco Chiarini, MSc, Luigi Grazioli, MD, Giuseppe Rossi, MD, Alessandra Tucci, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-135969

Published: 2020

Journal Articles

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

Samantha Ferrari, MD, Chiara Pagani, MD, Mariella D'Adda, MD, Nicola Bianchetti, MD, Annamaria Pelizzari, MD, Doriana Gramegna, MD, Chiara Bottelli, MD, Luisa Lorenzi, MD, Gabriella Vona, Alessandra Tucci, MD, Giuseppe Rossi, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-139431

Published: 2020

Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi

Blood (2019) 134 (Supplement_1): 4146.

https://doi.org/10.1182/blood-2019-125313

Published: 2019

Journal Articles

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

Samantha Ferrari, MD, Alessandra Tucci, Gloria Valimberti, MD, Antonella Anastasia, MD, Chiara Bottelli, MD, Marta Petullà, Marina Motta, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2018) 132 (Supplement 1): 5328.

https://doi.org/10.1182/blood-2018-99-114896

Published: 2018

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, MD, Monia Capponi, Achille Ambrosetti, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, MD, Luigi Rigacci, Gianluca Gaidano, MD PhD, Roberta Della Seta, Natalia Frattarelli, Paolo Falcucci, Giuseppe Visani, Robin Foà, MD, Brunangelo Falini, MD

Blood (2017) 130 (Supplement 1): 409.

https://doi.org/10.1182/blood.V130.Suppl_1.409.409

Published: 2017

Journal Articles

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Mariella D'adda, Mirko Farina, MD, Francesca Schieppati, MD, Elisa Cerqui, MD, Giuseppina Ruggeri, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Angela Passi, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 1589.

https://doi.org/10.1182/blood.V130.Suppl_1.1589.1589

Published: 2017

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

Mariella D'Adda, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Angela Passi, MD, Francesca Schieppati, MD, Rosaria Scaduto, Giuseppe Rossi, MD

Blood (2016) 128 (22): 5455.

https://doi.org/10.1182/blood.V128.22.5455.5455

Published: 2016

Journal Articles

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

Enrico Tiacci, Luca De Carolis, Francesco Zaja, Achille Ambrosetti, MD, Eugenio Lucia, Agostino Antolino, Alessandro Pulsoni, MD, Samantha Ferrari, MD, Pier Luigi Zinzani, Gianluca Gaidano, MD PhD, Robin Foà, Brunangelo Falini

Blood (2016) 128 (22): 1214.

https://doi.org/10.1182/blood.V128.22.1214.1214

Published: 2016

Journal Articles

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

Marina Motta, MD, Marco Chiarini, MSC, Marta Petullà, PharmD, Claudia Ghidini, BSC, Marion Vaglio Tessitore, BSC, Viviana Giustini, MSC, Chiara Pagani, MD, Antonella Anastasia, MD, Samantha Ferrari, MD, Alessandra Tucci, Luisa Imberti, MD, Giuseppe Rossi, MD

Blood (2015) 126 (23): 1531.

https://doi.org/10.1182/blood.V126.23.1531.1531

Published: 2015

Journal Articles

High Dose Melphalan Followed By Autologous Stem Cell Transplant in AL Amyloidosis: a Single-Center Experience

Mariella D'Adda, MD, Francesca Schieppati, MD, Samantha Ferrari, MD, Claudia Crippa, MD, Annalisa Peli, MD, Alessandro Re, MD, Enrico Morello, MD, Paola Tozzi, PharmD, Vincenza Orlando, PharmD, Giuseppe Rossi, MD

Blood (2014) 124 (21): 5909.

https://doi.org/10.1182/blood.V124.21.5909.5909

Published: 2014

Journal Articles

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

Blood (2013) 122 (8): 1376–1383.

https://doi.org/10.1182/blood-2013-02-483073

Published: 2013

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

Antonio Palumbo, MD, Alessandra Larocca, MD, Angelo Michele Carella, MD, Davide Rossi, Vittorio Montefusco, MD, Samantha Ferrari, MD, Alberto Santagostino, MD, Tommasina Guglielmelli, MD, Monica Galli, MD, Antonio Capaldi, MD, Nicola Giuliani, M.D., Ph.D., Giacinto La Verde, Paola Omedè, MD, Ileana Baldi, Mario Boccadoro, MD, Paolo Corradini, MD

Blood (2011) 118 (21): 632.

https://doi.org/10.1182/blood.V118.21.632.632

Published: 2011

Journal Articles

Bortezomib-Containing Regimens in the Treatment of AL Amyloidosis: A Single Center Experience

Alessandro Re, MD, Gina Gregorini, Annalisa Peli, MD, Matilde Nardi, Claudia Crippa, Samantha Ferrari, Laura Econimo, Chiara Cattaneo, Giovanni Cancarini, Giuseppe Rossi, MD

Blood (2011) 118 (21): 4614.

https://doi.org/10.1182/blood.V118.21.4614.4614

Published: 2011

Journal Articles

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Blood (2010) 115 (18): 3671–3677.

https://doi.org/10.1182/blood-2009-12-253856

Published: 2010

NARROW

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

How Many Chronic Myeloid Leukemia (CML) Patients in Chronic Phase (CP) Benefit from Treatment Free Remission? a Single Center Real-Life Experience

Failure to Achieve Sustained Imaging MRD Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Is Associated with Adverse Prognosis in Newly Diagnosed Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation Followed By Maintenance Therapy

Sustained Residual Disease Negativity Assessed By Diffusion-Weighted Whole-Body MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT)

Prognostic Factors for Developing Thrombosis in Polycytemia Vera: A Retrospective Analysis of 331 Patients with Long-Term Follow-up Highlights the Importance of White Blood Cells Levels

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Potentially Cured Follicular Lymphoma (PC-FL). an Analysis of 56 Cases with Prognostic Factors Evaluation

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

The Chemotherapy-Free Combination of Vemurafenib and Rituximab Produces Deep and Durable Responses in Relapsed or Refractory Hairy Cell Leukemia (HCL) Patients

An e13a2 Type of BCR-ABL Transcript Has a Significant Adverse Impact on the Achievement of a Sustained Deep Molecular Response and on the Maintenance of a Treatment Free Remission after Stopping Tyrosine Kinase Inhibitors

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

In Elderly Patients with CML Second Generation TKIs Are Very Effective and Can be Given Long Term Particularly in the Absence of Comorbidities: A Single Center Experience

Vemurafenib Plus Rituximab in Hairy Cell Leukemia: A Promising Chemotherapy-Free Regimen for Relapsed or Refractory Patients

Immunological Derangement in Follicular Lymphoma Patients Developing Severe Side Effects during Treatment with PI3K Inhibitors

High Dose Melphalan Followed By Autologous Stem Cell Transplant in AL Amyloidosis: a Single-Center Experience

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results

A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide

Bortezomib-Containing Regimens in the Treatment of AL Amyloidosis: A Single Center Experience

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only